- Home
- DEA vs OCUL Comparison
DEA vs OCUL Comparison
Compare DEA & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEA
- OCUL
- Stock Information
- Founded
- DEA 2011
- OCUL 2006
- Country
- DEA United States
- OCUL United States
- Employees
- DEA N/A
- OCUL N/A
- Industry
- DEA Real Estate Investment Trusts
- OCUL Biotechnology: Pharmaceutical Preparations
- Sector
- DEA Real Estate
- OCUL Health Care
- Exchange
- DEA Nasdaq
- OCUL Nasdaq
- Market Cap
- DEA 1.2B
- OCUL 1.4B
- IPO Year
- DEA 2015
- OCUL 2014
- Fundamental
- Price
- DEA $11.64
- OCUL $8.09
- Analyst Decision
- DEA Buy
- OCUL Strong Buy
- Analyst Count
- DEA 2
- OCUL 8
- Target Price
- DEA $12.50
- OCUL $16.50
- AVG Volume (30 Days)
- DEA 1.2M
- OCUL 842.8K
- Earning Date
- DEA 02-25-2025
- OCUL 03-10-2025
- Dividend Yield
- DEA 9.10%
- OCUL N/A
- EPS Growth
- DEA N/A
- OCUL N/A
- EPS
- DEA 0.17
- OCUL N/A
- Revenue
- DEA $302,121,000.00
- OCUL $61,442,000.00
- Revenue This Year
- DEA N/A
- OCUL $11.40
- Revenue Next Year
- DEA $9.77
- OCUL $13.58
- P/E Ratio
- DEA $68.24
- OCUL N/A
- Revenue Growth
- DEA 2.98
- OCUL 6.45
- 52 Week Low
- DEA $10.76
- OCUL $3.92
- 52 Week High
- DEA $14.53
- OCUL $11.78
- Technical
- Relative Strength Index (RSI)
- DEA 53.07
- OCUL 40.09
- Support Level
- DEA $10.99
- OCUL $7.99
- Resistance Level
- DEA $11.68
- OCUL $8.43
- Average True Range (ATR)
- DEA 0.23
- OCUL 0.38
- MACD
- DEA 0.08
- OCUL -0.02
- Stochastic Oscillator
- DEA 94.96
- OCUL 25.90
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.